PCI complications: Hemodynamic Support for Complex PCI: Difference between revisions

Jump to navigation Jump to search
 
Line 13: Line 13:
*[[Impella device|The Impella Percutaneous Left Ventricular–assist Devices]]
*[[Impella device|The Impella Percutaneous Left Ventricular–assist Devices]]
**This device provides greater [[left ventricle|left ventricular]] support.
**This device provides greater [[left ventricle|left ventricular]] support.
**[[Impella device]] provides better [[hemodynamic]] support compared with [[Intra-aortic balloon pump|balloon counterpulsation]]. 
**Nevertheless, usage of this device is limited in [[patients]] with [[left ventricular thrombus]], [[aortic stenosis]], [[peripheral artery disease]], or [[aorta|aortic]] [[disease]].
**Nevertheless, usage of this device is limited in [[patients]] with [[left ventricular thrombus]], [[aortic stenosis]], [[peripheral artery disease]], or [[aorta|aortic]] [[disease]].
*Extracorporeal membrane oxygenation and the Tandem-Heart devices
*Extracorporeal membrane oxygenation and the Tandem-Heart devices

Latest revision as of 14:41, 9 July 2022

Hemodynamic Support for Complex PC

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Anahita Deylamsalehi, M.D.[2]

Overview

Pathophysiology

Rapid hemodynamic deterioration and death during PCI can occur due to hypotension, decompensated heart failure, shock, or arrhythmias.[1][2][3]

Prevention

Usage of hemodynamic support devices can be helpful in specific circumstances nevertheless, its routine usage is not recommended to reduce cardiovascular events.[2][3]

Hemodynamic Support Devices

2021 ACA Revascularization Guideline

Class 2b Recommendation, Level of Evidence: B-R [1]
Using an appropriate hemodynamic support device in the elective settings and among selected patients is reasonable to prevent hemodynamic compromise during PCI.

References

  1. 1.0 1.1 1.2 1.3 Writing Committee Members. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM; et al. (2022). "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol. 79 (2): e21–e129. doi:10.1016/j.jacc.2021.09.006. PMID 34895950 Check |pmid= value (help).
  2. 2.0 2.1 Perera D, Stables R, Thomas M, Booth J, Pitt M, Blackman D; et al. (2010). "Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial". JAMA. 304 (8): 867–74. doi:10.1001/jama.2010.1190. PMID 20736470.
  3. 3.0 3.1 O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J; et al. (2012). "A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study". Circulation. 126 (14): 1717–27. doi:10.1161/CIRCULATIONAHA.112.098194. PMID 22935569.